RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Acceptability and use of the dapivirine vaginal ring and daily oral pre-exposure prophylaxis (PrEP) during breastfeeding in South Africa, Malawi, Zimbabwe, and Uganda
Stoner, M. C. D., Hawley, I., Mathebula, F., Horne, E., Etima, J., Kemigisha, D., Mutero, P., Dandadzi, A., Seyama, L., Fabiano, Z., Scheckter, R., Noguchi, L., Owor, M., Balkus, J. E., & Montgomery, E. T. (2023). Acceptability and use of the dapivirine vaginal ring and daily oral pre-exposure prophylaxis (PrEP) during breastfeeding in South Africa, Malawi, Zimbabwe, and Uganda. AIDS and Behavior, 27(12), 4114-4123. https://doi.org/10.1007/s10461-023-04125-w
This study examines qualitative acceptability of the dapivirine vaginal ring (DVR) and oral daily pre-exposure prophylaxis (PrEP) among breastfeeding persons participating in Microbicide Trials Network 043/B-PROTECTED, a phase 3B safety and drug detectability study of DVR and oral PrEP in breastfeeding. A subsample of 52 participants were purposively sampled to participate in an in-depth interview (IDI). Breastfeeding participants found both study products to be acceptable, and easy to use. A common motivation for product use was to protect the baby from HIV, although participants' understanding of how the study drug would work to protect their babies was often unclear. While most participants did not report experiencing side effects, fears about side effects were common as both initial worries about how the study products would affect their health and the health of their baby, and increased anxiety that health issues experienced by them, or their baby were from the products.
